{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:28:24Z","timestamp":1778858904552,"version":"3.51.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,7]]},"DOI":"10.7759\/cureus.19325","type":"journal-article","created":{"date-parts":[[2021,11,7]],"date-time":"2021-11-07T07:51:03Z","timestamp":1636271463000},"source":"Crossref","is-referenced-by-count":10,"title":["Endothelin Receptor Antagonists as a Potential Treatment of Diabetic Nephropathy: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Noorain","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harish","family":"Veerapalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chetan Reddy","family":"Lankala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Everardo E","family":"Castaneda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afia","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy G","family":"Rockferry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pousette","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"World Health Organization. Diabetes. (2021). Accessed: June 30, 2021: https:\/\/www.who.int\/health-topics\/diabetes."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.11070","article-title":"Diabetic kidney disease in type 2 diabetes: a review of pathogenic mechanisms, patient-related factors and therapeutic options","volume":"9","author":"Woodhams L","year":"2021","unstructured":"Woodhams L, Sim TF, Chalmers L, et al.. Diabetic kidney disease in type 2 diabetes: a review of pathogenic mechanisms, patient-related factors and therapeutic options. PeerJ. 2021, 9:e11070. 10.7717\/peerj.11070","journal-title":"PeerJ"},{"key":"ref3","unstructured":"Centers for Disease Control and Prevention. Diabetes and chronic kidney disease. (2021). Accessed: July 1, 2021: https:\/\/www.cdc.gov\/diabetes\/managing\/diabetes-kidney-disease.html."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2012.04.026","article-title":"Update on potential drugs for the treatment of diabetic kidney disease","volume":"34","author":"Shepler B","year":"2012","unstructured":"Shepler B, Nash C, Smith C, Dimarco A, Petty J, Szewciw S. Update on potential drugs for the treatment of diabetic kidney disease. Clin Ther. 2012, 34:1237-46. 10.1016\/j.clinthera.2012.04.026","journal-title":"Clin Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities","volume":"12","author":"Alicic RZ","year":"2017","unstructured":"Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017, 12:2032-45. 10.2215\/CJN.11491116","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.5772\/22795","article-title":"Diabetic glomerulopathy","author":"Barazi M","year":"2011","unstructured":"Barazi M, Kaur H, Prabhakar S. Diabetic glomerulopathy. An Update on Glomerulopathies - Clinical and Treatment Aspects. Prabhakar S (ed): IntechOpen, 2011. 327-368. 10.5772\/22795"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-43359-2","article-title":"Pathophysiology of diabetic nephropathy","author":"Herman M","year":"2016","unstructured":"Herman M, Doi S. Pathophysiology of diabetic nephropathy. Proteinuria: Basic Mechanisms, Pathophysiology and Clinical Relevance. Blaine J (ed): Springer International Publishing, 2016. 41-65. 10.1007\/978-3-319-43359-2"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2009060593","article-title":"Avosentan for overt diabetic nephropathy","volume":"21","author":"Mann JF","year":"2010","unstructured":"Mann JF, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T, Viberti G. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol. 2010, 21:527-35. 10.1681\/ASN.2009060593","journal-title":"J Am Soc Nephrol"},{"key":"ref9","unstructured":"National Institute for Health and Care Excellence. Chronic kidney disease: assessment and management. (2021). Accessed: July 9, 2021: https:\/\/www.nice.org.uk\/guidance\/ng203\/chapter\/Recommendations."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.17925\/EE.2012.08.01.32","article-title":"Endothelin receptor antagonists in diabetic nephropathy","volume":"8","author":"Wenzel R","year":"2012","unstructured":"Wenzel R, Ritz E, Wenzel M. Endothelin receptor antagonists in diabetic nephropathy. Tou Endo. 2012, 8:32-5. 10.17925\/EE.2012.08.01.32","journal-title":"Tou Endo"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1900\/RDS.2015.12.119","article-title":"Improvements in the management of diabetic nephropathy","volume":"12","author":"Dounousi E","year":"2015","unstructured":"Dounousi E, Duni A, Leivaditis K, Vaios V, Eleftheriadis T, Liakopoulos V. Improvements in the management of diabetic nephropathy. Rev Diabet Stud. 2015, 12:119-33. 10.1900\/RDS.2015.12.119","journal-title":"Rev Diabet Stud"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v11.i11.553","article-title":"Endothelin receptor antagonists for the treatment of diabetic nephropathy: a meta-analysis and systematic review","volume":"11","author":"Zhang L","year":"2020","unstructured":"Zhang L, Xue S, Hou J, Chen G, Xu ZG. Endothelin receptor antagonists for the treatment of diabetic nephropathy: a meta-analysis and systematic review. World J Diabetes. 2020, 11:553-66. 10.4239\/wjd.v11.i11.553","journal-title":"World J Diabetes"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1080\/20009666.2018.1500423","article-title":"Diabetic nephropathy: newer therapeutic perspectives","volume":"8","author":"Keri KC","year":"2018","unstructured":"Keri KC, Samji NS, Blumenthal S. Diabetic nephropathy: newer therapeutic perspectives. J Community Hosp Intern Med Perspect. 2018, 8:200-7. 10.1080\/20009666.2018.1500423","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2013080830","article-title":"The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy","volume":"25","author":"de Zeeuw D","year":"2014","unstructured":"de Zeeuw D, Coll B, Andress D, et al.. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J Am Soc Nephrol. 2014, 25:1083-93. 10.1681\/ASN.2013080830","journal-title":"J Am Soc Nephrol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/jcm4061171","article-title":"Endothelin blockade in diabetic kidney disease","volume":"4","author":"Anguiano L","year":"2015","unstructured":"Anguiano L, Riera M, Pascual J, Soler MJ. Endothelin blockade in diabetic kidney disease. J Clin Med. 2015, 4:1171-92. 10.3390\/jcm4061171","journal-title":"J Clin Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014020174","article-title":"Endothelin antagonists in diabetic nephropathy: back to basics","volume":"25","author":"Chandrashekar K","year":"2014","unstructured":"Chandrashekar K, Juncos LA. Endothelin antagonists in diabetic nephropathy: back to basics. J Am Soc Nephrol. 2014, 25:869-71. 10.1681\/ASN.2014020174","journal-title":"J Am Soc Nephrol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14411","article-title":"Efficacy and safety of endothelin receptor antagonists in type 2 diabetic kidney disease: a systematic review and meta-analysis of randomized controlled trials","volume":"38","author":"Zhou Y","year":"2021","unstructured":"Zhou Y, Chi J, Huang Y, Dong B, Lv W, Wang YG. Efficacy and safety of endothelin receptor antagonists in type 2 diabetic kidney disease: a systematic review and meta-analysis of randomized controlled trials. Diabet Med. 2021, 38:e14411. 10.1111\/dme.14411","journal-title":"Diabet Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins JP","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al.. The Cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011, 343:d5928. 10.1136\/bmj.d5928","journal-title":"BMJ"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2008050482","article-title":"Avosentan reduces albumin excretion in diabetics with macroalbuminuria","volume":"20","author":"Wenzel RR","year":"2009","unstructured":"Wenzel RR, Littke T, Kuranoff S, et al.. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol. 2009, 20:655-64. 10.1681\/ASN.2008050482","journal-title":"J Am Soc Nephrol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-011-2415-y","article-title":"The endothelin receptor antagonist bosentan improves peripheral endothelial function in patients with type 2 diabetes mellitus and microalbuminuria: a randomised trial","volume":"55","author":"Rafnsson A","year":"2012","unstructured":"Rafnsson A, B\u00f6hm F, Settergren M, Gonon A, Brismar K, Pernow J. The endothelin receptor antagonist bosentan improves peripheral endothelial function in patients with type 2 diabetes mellitus and microalbuminuria: a randomised trial. Diabeto. 2012, 55:600-7. 10.1007\/s00125-011-2415-y","journal-title":"Diabeto"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2010080869","article-title":"Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy","volume":"22","author":"Kohan DE","year":"2011","unstructured":"Kohan DE, Pritchett Y, Molitch M, Wen S, Garimella T, Audhya P, Andress DL. Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol. 2011, 22:763-72. 10.1681\/ASN.2010080869","journal-title":"J Am Soc Nephrol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2012.01.011","article-title":"Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD)","volume":"91","author":"Andress DL","year":"2012","unstructured":"Andress DL, Coll B, Pritchett Y, Brennan J, Molitch M, Kohan DE. Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD). Life Sci. 2012, 91:739-42. 10.1016\/j.lfs.2012.01.011","journal-title":"Life Sci"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00570115","article-title":"Predictors of atrasentan-associated fluid retention and change in albuminuria in patients with diabetic nephropathy","volume":"10","author":"Kohan DE","year":"2015","unstructured":"Kohan DE, Heerspink LHJ, Coll B, et al.. Predictors of atrasentan-associated fluid retention and change in albuminuria in patients with diabetic nephropathy. Clin J Am Soc Nephrol. 2015, 10:1568-74. 10.2215\/CJN.00570115","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1177\/2047487315598709","article-title":"Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers","volume":"23","author":"Schievink B","year":"2016","unstructured":"Schievink B, de Zeeuw D, Smink PA, et al.. Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers. Eur J Prev Cardiol. 2016, 23:758-68. 10.1177\/2047487315598709","journal-title":"Eur J Prev Cardiol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12864","article-title":"The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy","volume":"19","author":"Pena MJ","year":"2017","unstructured":"Pena MJ, de Zeeuw D, Andress D, et al.. The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy. Diabetes Obes Metab. 2017, 19:749-53. 10.1111\/dom.12864","journal-title":"Diabetes Obes Metab"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13312","article-title":"Determining the optimal dose of atrasentan by evaluating the exposure-response relationships of albuminuria and bodyweight","volume":"20","author":"Koomen JV","year":"2018","unstructured":"Koomen JV, Stevens J, Mostafa NM, Parving HH, de Zeeuw D, Heerspink HJ. Determining the optimal dose of atrasentan by evaluating the exposure-response relationships of albuminuria and bodyweight. Diabetes Obes Metab. 2018, 20:2019-22. 10.1111\/dom.13312","journal-title":"Diabetes Obes Metab"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.07.011","article-title":"Relationship between atrasentan concentrations and urinary albumin to creatinine ratio in Western and Japanese patients with diabetic nephropathy","volume":"40","author":"Lin CW","year":"2018","unstructured":"Lin CW, Mostafa NM, Andress DL, Brennan JJ, Klein CE, Awni WM. Relationship between atrasentan concentrations and urinary albumin to creatinine ratio in Western and Japanese patients with diabetic nephropathy. Clin Ther. 2018, 40:242-51. 10.1016\/j.clinthera.2017.07.011","journal-title":"Clin Ther"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-017-0201-0","article-title":"Longitudinal assessment of the effect of atrasentan on thoracic bioimpedance in diabetic nephropathy: a randomized, double-blind, placebo-controlled trial","volume":"17","author":"Webb DJ","year":"2017","unstructured":"Webb DJ, Coll B, Heerspink HJ, et al.. Longitudinal assessment of the effect of atrasentan on thoracic bioimpedance in diabetic nephropathy: a randomized, double-blind, placebo-controlled trial. Drugs R D. 2017, 17:441-8. 10.1007\/s40268-017-0201-0","journal-title":"Drugs R D"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink HJL","year":"2019","unstructured":"Heerspink HJL, Parving HH, Andress DL, et al.. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet. 2019, 393:1937-1947. 10.1016\/S0140-6736(19)30772-X","journal-title":"Lancet"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14252","article-title":"Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: a post hoc analysis of the SONAR trial","volume":"23","author":"Koomen JV","year":"2021","unstructured":"Koomen JV, Stevens J, Bakris G, et al.. Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: a post hoc analysis of the SONAR trial. Diabetes Obes Metab. 2021, 23:561-8. 10.1111\/dom.14252","journal-title":"Diabetes Obes Metab"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/nep.12442","article-title":"Endothelin-receptor antagonists for diabetic nephropathy: a meta-analysis","volume":"20","author":"Yuan W","year":"2015","unstructured":"Yuan W, Li Y, Wang J, Li J, Gou S, Fu P. Endothelin-receptor antagonists for diabetic nephropathy: a meta-analysis. Nephrol. 2015, 20:459-66. 10.1111\/nep.12442","journal-title":"Nephrol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003224","article-title":"Relationship between dyslipidemia and albuminuria in hypertensive adults: a nationwide population-based study","volume":"95","author":"Lee SH","year":"2016","unstructured":"Lee SH, Kim DH, Kim YH, et al.. Relationship between dyslipidemia and albuminuria in hypertensive adults: a nationwide population-based study. Medic. 2016, 95:e3224. 10.1097\/MD.0000000000003224","journal-title":"Medic"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-6-443","article-title":"Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on hemoglobin levels","volume":"6","author":"Ajmal A","year":"2013","unstructured":"Ajmal A, Gessert CE, Johnson BP, Renier CM, Palcher JA. Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on hemoglobin levels. BMC Res Notes. 2013, 6:443. 10.1186\/1756-0500-6-443","journal-title":"BMC Res Notes"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.09.026","article-title":"New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction","volume":"99","author":"Heerspink HJ","year":"2021","unstructured":"Heerspink HJ, Kohan DE, de Zeeuw D. New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction. Kidney Int. 2021, 99:346-9. 10.1016\/j.kint.2020.09.026","journal-title":"Kidney Int"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.08540719","article-title":"SONAR: do a new design and statistically significant results translate to reliability?","volume":"15","author":"Walsh M","year":"2020","unstructured":"Walsh M. SONAR: do a new design and statistically significant results translate to reliability?. Clin J Am Soc Nephrol. 2020, 15:889-91. 10.2215\/CJN.08540719","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/72584-endothelin-receptor-antagonists-as-a-potential-treatment-of-diabetic-nephropathy-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:33:27Z","timestamp":1707507207000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/72584-endothelin-receptor-antagonists-as-a-potential-treatment-of-diabetic-nephropathy-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,7]]},"references-count":36,"URL":"https:\/\/doi.org\/10.7759\/cureus.19325","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,7]]}}}